Drug intelligence / Profile preview

CoronaVac + Inlive

Development stage
Unknown
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

CoronaVac + Inlive is a vaccine combination regimen consisting of the simultaneous administration of two separate inactivated vaccines developed by Sinovac Biotech: CoronaVac (an inactivated SARS-CoV-2 vaccine) and Inlive (an inactivated Enterovirus 71 vaccine). CoronaVac is derived from the CZ02 strain of SARS-CoV-2, while Inlive is derived from the H07 strain (subgenotype C4) of Enterovirus 71. Both vaccines are produced using Vero cells and are formulated with aluminum hydroxide as an adjuvant. This co-administration approach was specifically evaluated in Phase IV clinical trials to determine the safety and immunogenicity of providing protection against both COVID-19 and Hand, Foot, and Mouth Disease (HFMD) in pediatric populations, specifically children aged 3 to 5 years.

Brand names
CoronaVacInlive
Other names
COVID-19 vaccine (Vero cell), InactivatedEV71 vaccine (Vero cell), InactivatedEnterovirus Type 71 Vaccine (Inactivated, Vero Cell)

Beyond the preview

Go deeper on CoronaVac + Inlive.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoronaVac + Inlive.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call